C12N 9/6467
Granzymes
Official title: {Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)}
C12N9/6467 (Granzymes) appears on 52 US grants and 67 published applications in this corpus.
Search patents in C12N- Granted patents
- 52
- Published applications
- 67
- Assignees
- 52
- Inventors
- 160
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 6 | 0 |
| 2001 | 5 | 0 |
| 2002 | 2 | 1 |
| 2003 | 3 | 4 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 2 | 4 |
| 2007 | 1 | 4 |
| 2008 | 1 | 0 |
| 2009 | 0 | 4 |
| 2010 | 2 | 0 |
| 2011 | 2 | 2 |
| 2012 | 0 | 2 |
| 2013 | 2 | 0 |
| 2014 | 0 | 4 |
| 2015 | 1 | 3 |
| 2016 | 2 | 1 |
| 2017 | 2 | 6 |
| 2018 | 2 | 2 |
| 2019 | 2 | 4 |
| 2020 | 3 | 2 |
| 2021 | 2 | 2 |
| 2022 | 3 | 3 |
| 2023 | 0 | 3 |
| 2024 | 1 | 5 |
| 2025 | 0 | 5 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing10 Mar 2026US 12,570,968 B2The Regents of the University of California
- Cell-targeted cytotoxic constructs27 Feb 2024US 11,913,043 B2Research Development Foundation
- Serine protease molecules and therapies27 Dec 2022US 11,535,838 B2Research Development Foundation
- Adjuvant composition and use thereof12 Jul 2022US 11,382,973 B2Riken
- Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing12 Jul 2022US 11,384,350 B2The Regents of the University of California
- Engineered natural killer cells with enhanced antitumor memory responses3 Sep 2026US 2026/0258360 A1Board of Regents, The University of Texas System
- Granzyme expressing t cells and methods of use27 Aug 2026US 2026/0248851 A1The Regents of the University of Colorado, a body corporate
- Car molecule, cell or exosome containing same, and use thereof6 Aug 2026US 2026/0226159 A1Wuhan Zhaozhi Biotechnology Co., Ltd
- Chimeric antigen receptor modified regulatory t cells for treating cancer24 Jul 2025US 2025/0235478 A1MUSC Foundation for Research Development
- Systems and Methods Incorporating Modified T-Cells27 Feb 2025US 2025/0066729 A1
Most cited
By later US patents
- Compositions and methods for the treatment and diagnosis of immune disorders111US 6,562,343 B1Millennium Pharmaceuticals, Inc. · 2003
- Compositions and methods for the treatment and diagnosis of immune disorders106US 6,414,117 B1Millennium Pharmaceuticals, Inc. · 2002
- Compositions and methods for the treatment and diagnosis of immune disorders65US 6,204,371 B1Millennium Pharmaceuticals, Inc. · 2001
- Human serine protease precursor64US 5,858,758 AIncyte Pharmaceuticals, Inc. · 1999
- Compositions and methods for the treatment and diagnosis of immune disorders57US 6,288,218 B12001